Mycoplasma genitalium Diagnosis and Treatment Guidelines

Diagnosis

Nucleic acid amplification testing (NAAT) is the only acceptable diagnostic method for M. genitalium, as culture is impractical due to the organism's slow growth characteristics, according to the Clinical Infectious Diseases guidelines 1
First-void urine in men and vaginal swabs (self-collected or provider-collected) in women are recommended specimen collection methods for M. genitalium detection, as suggested by the Clinical Infectious Diseases guidelines 1
Endocervical swabs are acceptable alternatives for specimen collection, as stated by the Clinical Infectious Diseases guidelines 1
Rectal and pharyngeal specimens can be tested but require laboratory validation, according to the Clinical Infectious Diseases guidelines 1
No FDA-cleared commercial NAAT is currently available for M. genitalium detection, as noted by the Clinical Infectious Diseases guidelines 1
Standardized diagnostic tests are not commercially available in many settings, as reported by the MMWR Recommendations and Reports guidelines 2, 3

Azithromycin 500 mg orally on day 1, then 250 mg orally daily on days 2-5 is the recommended first-line treatment for uncomplicated M. genitalium infection without documented macrolide resistance, as recommended by the European Urology guidelines 4, 5
Moxifloxacin 400 mg orally once daily for 7 days (uncomplicated) or 14 days (complicated infections including PID or epididymitis) should be used for macrolide-resistant M. genitalium or after azithromycin failure, as suggested by the European Urology guidelines 4, 5

All sexual partners within the preceding 60 days must be evaluated and treated simultaneously, regardless of symptoms, to prevent reinfection and ongoing transmission, as recommended by the European Urology and Praxis Medical Insights guidelines 5, 6
Patients must abstain from sexual intercourse until 7 days after completing therapy, and partners must also abstain until completing their own treatment course, as advised by the Praxis Medical Insights guidelines 6
Test of cure is not routinely recommended unless symptoms persist, but patients should return if symptoms persist or recur after treatment, as suggested by the Praxis Medical Insights guidelines 6, 7
Consider repeat testing at 3-6 months due to high reinfection rates, as recommended by the Praxis Medical Insights guidelines 6
HIV-infected patients receive the same treatment regimens as HIV-negative patients, as stated by the Praxis Medical Insights guidelines 7
M. genitalium is recognized as an emerging STI of public health concern requiring partner notification, as noted by the Praxis Medical Insights guidelines 8

Untreated or inadequately treated partners are the primary cause of persistent infection, with reinfection accounting for most post-treatment infections, according to the MMWR Recommendations and Reports 9
Most post-treatment infections result from reinfection, not treatment failure, as stated by the MMWR Recommendations and Reports 9
Repeat infections confer elevated risk for PID and complications compared to initial infection, as noted by the MMWR Recommendations and Reports 9
Recently infected individuals are high priority for retesting, according to the MMWR Recommendations and Reports 9

If testing is performed, wait at least 3 weeks after treatment completion to avoid false-positive results from dead organisms, as recommended by the MMWR Recommendations and Reports 9

Do not perform test-of-cure earlier than 3 weeks post-treatment, as false-positives from dead organisms are common, according to the MMWR Recommendations and Reports 9

Men with Mycoplasma genitalium infection may experience urethral discomfort or irritation, according to the MMWR Recommendations and Reports 10

Women with Mycoplasma genitalium infection may present with abnormal vaginal discharge, intermenstrual vaginal bleeding, and signs of cervicitis, including purulent endocervical exudate and sustained endocervical bleeding induced by gentle swabbing, as reported by the MMWR Recommendations and Reports 11, 12
The Centers for Disease Control and Prevention, as stated in the MMWR Recommendations and Reports, notes that Mycoplasma genitalium can cause pelvic inflammatory disease (PID) 11